Media coverage about AMAG Pharmaceuticals (NASDAQ:AMAG) has been trending somewhat positive on Friday, AlphaOne Sentiment Analysis reports. The research group, a division of Accern, identifies negative and positive media coverage by monitoring more than 20 million news and blog sources in real-time. AlphaOne ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. AMAG Pharmaceuticals earned a media sentiment score of 0.13 on AlphaOne’s scale. AlphaOne also gave media coverage about the specialty pharmaceutical company an impact score of 61 out of 100, meaning that recent media coverage is somewhat likely to have an effect on the stock’s share price in the immediate future.
Here are some of the news headlines that may have impacted Alpha One Sentiment’s analysis:
- AMAG Pharmaceuticals, Inc. (AMAG) Given Consensus Recommendation of “Hold” by Analysts (americanbankingnews.com)
- Is Amag Pharmaceuticals Incorporated (NASDAQ:AMAG) a Buy? The Stock Reported more Sellers – Weekly Register (weeklyregister.com)
- AMAG Pharmaceuticals, Inc. (AMAG) Reaches 52-Week High – Highlight Press (highlightpress.com)
- TRI Pointe Group (TPH) Earns Daily Coverage Optimism Score of 0.45 (leisuretravelaid.com)
- AMAG Pharmaceuticals Has Returned 35.9% Since SmarTrend Recommendation (AMAG) (mysmartrend.com)
A number of research firms have recently commented on AMAG. Barclays PLC reiterated an “equal weight” rating and issued a $20.00 price objective (down previously from $25.00) on shares of AMAG Pharmaceuticals in a report on Thursday, June 1st. ValuEngine downgraded AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. TheStreet downgraded AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Jefferies Group LLC reiterated a “buy” rating and issued a $34.00 price objective (down previously from $40.00) on shares of AMAG Pharmaceuticals in a report on Wednesday, May 3rd. Finally, Cantor Fitzgerald restated a “hold” rating and set a $23.00 price target on shares of AMAG Pharmaceuticals in a research note on Tuesday, May 2nd. Three analysts have rated the stock with a sell rating, seven have assigned a hold rating and two have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $29.44.
Shares of AMAG Pharmaceuticals (NASDAQ AMAG) traded up 1.86% on Friday, hitting $16.40. The company’s stock had a trading volume of 1,327,427 shares. The company has a 50 day moving average of $18.71 and a 200 day moving average of $24.24. The firm’s market cap is $574.74 million. AMAG Pharmaceuticals has a 1-year low of $16.00 and a 1-year high of $36.83.
AMAG Pharmaceuticals (NASDAQ:AMAG) last released its earnings results on Tuesday, May 2nd. The specialty pharmaceutical company reported ($1.06) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of $0.09 by $1.15. AMAG Pharmaceuticals had a negative net margin of 5.61% and a positive return on equity of 1.69%. The company had revenue of $139.47 million during the quarter, compared to the consensus estimate of $150.32 million. During the same quarter in the previous year, the business posted ($0.22) EPS. The firm’s quarterly revenue was up 27.6% on a year-over-year basis. Equities analysts forecast that AMAG Pharmaceuticals will post $5.07 EPS for the current year.
In related news, SVP Julie Krop sold 1,891 shares of the stock in a transaction dated Monday, May 1st. The shares were sold at an average price of $24.45, for a total value of $46,234.95. Following the completion of the sale, the senior vice president now owns 36,777 shares in the company, valued at $899,197.65. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. 3.80% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: “AMAG Pharmaceuticals (AMAG) Receiving Somewhat Favorable News Coverage, Analysis Finds” was first published by Chaffey Breeze and is owned by of Chaffey Breeze. If you are reading this report on another website, it was illegally copied and reposted in violation of United States and international trademark & copyright laws. The legal version of this report can be read at https://www.chaffeybreeze.com/2017/06/17/amag-pharmaceuticals-amag-getting-somewhat-favorable-news-coverage-alphaone-reports-updated-updated.html.
AMAG Pharmaceuticals Company Profile
AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.
Receive News & Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.